Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: A randomized clinical trial

American Journal of Clinical Nutrition

Volumn 95, Issue 3, 2012, Pages 678-685

  Arpadi, Stephen M ^a,b,d   McMahon, Donald J ^b   Abrams, Elaine J ^b,c   Bamji, Mahrukh ^e   Purswani, Murli ^f   Engelson, Ellen S ^b,d   Horlick, Mary ^g   Shane, Elizabeth ^b  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b Harlem Hospital Center ^*  (United States)

^c HARLEM HOSPITAL CENTER   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^e METROPOLITAN HOSPITAL CENTER   (United States)

^f BRONX LEBANON HOSPITAL CENTER   (United States)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; COLECALCIFEROL; PLACEBO;

ADOLESCENT; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CHILD; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEXUAL MATURATION; STATISTICAL MODEL; SUPPLEMENTATION; THERAPY EFFECT; VITAMIN SUPPLEMENTATION;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; BONE AND BONES; BONE DENSITY; CALCIUM, DIETARY; CHILD; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; QUESTIONNAIRES; VITAMIN D DEFICIENCY;

EID: 84857871247     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.111.024786     Document Type: Article

References (61)

1. Mora S, Sala N, Bricalli D, Chiuimello G, Zuin G, Chiumella G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001;15:1823-9. (Pubitemid 32939243)
2. O'Brien KO, Razavi M, Henderson R, Caballero B, Ellis K. Bone mineral content in girls perinatally infected with HIV. Am J Clin Nutr 2001;73:821-6. (Pubitemid 32239238)
3. Arpadi SM, Horlick M, Thornton J, Wang J, Kotler D. Bone mineral content is lower in HIV-infected children. J Acquir Imm Def Syndr 2002;29:450-4. (Pubitemid 34456335)
4. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Viganò A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004;89:24-8. (Pubitemid 38183854)
5. Rojo Conejo P, Ramos Amador JT, García Piñar L, Ruano Fajardo C, Sánchez Granados JM, González Tomé MI, Ruiz Contreras J. Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy. Anal Pediatr (Barc) 2004;60:249-53. (Pubitemid 38596063)
6. Jacobson DL, Spiegelman D, Duggan C, Weinberg GA, Bechard L, Furuta L, Nicchitta J, Gorbach SL, Miller TL. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastroenterol Nutr 2005;41:339-46. (Pubitemid 41285829)
7. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kb ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005;150:67-78. (Pubitemid 40171950)
8. Gibellini D, Crignis E, Ponti C, Cimatti L, Borderi M, Tschon M, Giardino R, Re MC. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFα activation. J Med Virol 2008;80:1507-14.
9. Zuccotti G, Viganó A, Gabiano C, Giacomet V, Mignone F, Stucchi S, Manfredini V, Marinacci F, Mora S. Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone 2010;46:1633-8.
10. Fassler ALC, Bonjour JP. Osteoporosis as a pediatric problem. Pediatr Nutr 1996;2:811-23.
11. Seeman E. From density to structure: growing up and growing old on the surfaces of bone. J Bone Miner Res 1997;12:509-21. (Pubitemid 27155210)
12. Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA. A six year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: The University of Saskatchewan bone mineral accrual study. J Bone Miner Res 1999;14:1672-9. (Pubitemid 29455815)
13. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17:1-45.
14. Goulding A, Jones IE, Taylor RW, Williams SM, Manning PJ. Bone mineral density and body composition in boys with distal forearm fractures: A dual-energy x-ray absorptiometry study. J Pediatr 2001;139:509-15. (Pubitemid 32977264)
15. Jones IE, Taylor RW, Williams SM, Manning PJ, Goulding A. Four-year gain in bone mineral in girls with and without past forearm fractures: a DXA study. J Bone Miner Res 2002;17:1065-72. (Pubitemid 34535145)
16. Goulding A, Grant A, Williams S. Bone and body composition of children and adolescents with repeated forearm fractures. J Bone Miner Res 2005;20:2090-6. (Pubitemid 41698772)
17. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ. Prevalence of vitamin D deficiency among health adolescents. Arch Pediatr Adolesc Med 2004;158:531-7. (Pubitemid 38720483)
18. Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr 2006;83:1135-41. (Pubitemid 44713115)
19. Arpadi SM, McMahon D, Abrams EJ, Bamji M, Purswani M, Engelson ES, Horlick M, Shane E. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics 2009;123:e121-6.
20. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso A. HIV-protease inhibitors impair vitamin D bioactivation to 1, 25-dihydroxyvitamin D. AIDS 2003;17:513-20. (Pubitemid 36293104)
21. Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, Post FA. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010;24:1923-8.
22. Jekovec-Vrhovsek M, Kocijancic A, Preselj J. Effect of vitamin D and calcium on bone mineral density in children with CP and epilepsy in full-time care. Dev Med Child Neurol 2000;42:403-5. (Pubitemid 30326664)
23. Bak M, Serdaroglu E, Guclu R. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. Pediatr Nephrol 2006;21:350-4. (Pubitemid 43280350)
24. Lovell DJ, Glass D, Ranz J, Kramer S, Huang B, Sierra RI, Henderson CJ, Passo M, Graham B, Bowyer S, et al. A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:2235-42. (Pubitemid 44051080)
25. Guillemant J, Le HT, Maria A, Allemandu A, Peres G, Guillemant S. Wintertime vitamin D deficiency in male adolescents: effect on parathyroid function and response to vitamin D3 supplements. Osteoporos Int 2001;12:875-9. (Pubitemid 33086276)
26. US Pharmacopeia. Rockville, MD: US Pharmacopeial Convention Inc, 2002.
27. Marshall WA, Tanner JM. Variations in patterns of pubertal changes in boys. Arch Dis Child 1970;45:13-23.
28. Marshall WA, Tanner JM. Variations in patterns of pubertal changes in girls. Arch Dis Child 1969;44:291-303.
29. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 43(RR-12);1-10 [Publication date 30 September 1994].
30. Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, Mahboubi S, Fan B, Frederick MM, Winer K, et al. The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab 2007;92:2087-99. (Pubitemid 46997105)
31. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003;78:1463-70. (Pubitemid 37475629)
32. Lloyd T, Martel JK, Rollings N, Andon MB, Kulin H, Demers LM, Eggli DF, Kieselhorst K, Chinchilli VM. The effect of calcium supplementation and Tanner stage on bone density, content and area in teenage women. Osteoporos Int 1996;6:276-83. (Pubitemid 26280820)
33. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006;84:18-28. ((Published erratum appears in Am J Clin Nutr 2006;84:1253 and Am J Clin Nutr 2007;86:809.) (Pubitemid 47435859)
34. Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, Hoffmann ME, Tebas P. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005;38:426-31. (Pubitemid 40381552)
35. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007;21:2473-82. (Pubitemid 350145179)
36. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005;135:317-22. (Pubitemid 40194499)
37. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998;351:805-6. (Pubitemid 28112350)
38. Heaney RP. The vitamin D requirements in health and disease. J Steroid Biochem Mol Biol 2005;97:13-9.
39. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-6. (Pubitemid 40933586)
40. Heaney RP, Dowell M, Hale C, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22:142-6. (Pubitemid 36417827)
41. Bischoff-Ferrari HA, Dietrich T, Orav E, Dawson-Hughes B. Positive association between 25(OH)D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004;116:634-9. (Pubitemid 38490539)
42. Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 2008;624:55-71.
43. Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother 2008;9:107-18. (Pubitemid 351233752)
44. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, El-Hajj Fuleihan G, Josse RG, Lips P, Morales-Torres J. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009;20:1807-20.
45. Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007;85:649-50. (Pubitemid 46393494)
46. Institute of Medicine. Dietary reference for intake of calcium and vitamin D. 2010 Report Brief, Institute of Medicine. Available from: http://iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for- Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium% 202010%20Report%20Brief.pdf (cited 7 March 2011).
47. Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 2008;87:1738-42. (Pubitemid 351872637)
48. Leventis P, Kiely PD. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scand J Rheumatol 2009;38:149-53.
49. Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr 2008;87:688-91. (Pubitemid 351364551)
50. Bonjour J-P, Carrie A-L, Ferrari S, Clavien H, Slosman D, Theintz G, Rizzoli R. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 1997;99:1287-94. (Pubitemid 27142766)
51. Johnston CC, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, Peacock M. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992;327:82-7.
52. Lee WTK, Leung SSF, Leung DMY, Tsang HSY, Lau J, Cheng JCY. A randomized double-blind controlled calcium supplementation trial, and bone and height acquisition in children. Br J Nutr 1995;74:125-39.
53. Lloyd T, Andon MB, Rollings N, Martel JK, Landis JR, Demers LM, Eggli DF, Kieselhorst K, Kulin HE. Calcium supplementation and bone mineral density in adolescent girls. JAMA 1993;270:841-4. (Pubitemid 23234112)
54. Aukrust P, Haug CJ, Ueland T, Lien E, Müller F, Espevik T, Bollerslev J, Frøland SS. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication ofnormalization of the bone remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999;84:145-50. (Pubitemid 29036693)
55. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M, Tebas P. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virusinfected individuals. Clin Infect Dis 2003;36:482-90. (Pubitemid 36241317)
56. Wang MW, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, Teitelbaum SL, Ross FP. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004;114:206-13. (Pubitemid 39071625)
57. Malizia AP, Cotter E, Chew N, Powderly WG, Doran PP. HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Res Hum Retroviruses 2007;23:243-50. (Pubitemid 46418337)
58. Fakruddin JM, Laurence J. HIV envelope gp-120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kb ligand (RANKL) decretion and its modulation by certain HIV protease inhibitors through interferon-γ /RANKL cross-talk. J Biol Chem 2003; 278:48251-8. (Pubitemid 37523280)
59. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
60. van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, Sutinen J, Ristola M, Danner SA, Reiss P. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009;23:1367-76.
61. de Martino M, Tovo PA, Galli L, Gabiano C, Chiarelli F, Zappa M, Gattinara GC, Bassetti D, Giacomet V, Chiappini E, et al. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS 2001;15:1527-34. (Pubitemid 32744600)